KLS Keeping Law Simple Legislation in plain English

Straight-ahead summaries built from the official bill text. We keep the source links front and center and leave the decision up to you.

Back to Washington

HB1741 • 2026

PANDAS, pediatric treatment

Expanding access to treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute-onset neuropsychiatric syndrome.

Passed Legislature

This bill passed both chambers and reached final enrollment, even if later executive action is not shown here.

Sponsor
Representative Thai, Representative Leavitt, Representative Paul, Representative Simmons, Representative Couture, Representative Parshley, Representative Fey, Representative Duerr, Representative Nance, Representative Davis
Last action
2026-01-12
Official status
H HC/Wellness
Effective date
Not listed

Plain English Breakdown

Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.

PANDAS, pediatric treatment

PANDAS, pediatric treatment

What This Bill Does

  • PANDAS, pediatric treatment

Limits and Unknowns

  • This entry is temporarily using official source text because the generated explanation could not be confirmed against the official bill text during the last sync.

Bill History

  1. 2026-01-12 House

    By resolution, reintroduced and retained in present status.

Official Summary Text

PANDAS, pediatric treatment

Current Bill Text

Read the full stored bill text 
AN ACT Relating to expanding access to treatment of pediatric 1
autoimmune neuropsychiatric disorders associated with streptococcal 2
infections and pediatric acute-onset neuropsychiatric syndrome; and 3
adding a new section to chapter 48.43 RCW. 4
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:5
NEW SECTION. Sec. 1. A new section is added to chapter 48.43 6
RCW to read as follows: 7
(1) For health plans other than health plans offered to public 8
employees and dependents under chapter 41.05 RCW issued or renewed on 9
or after January 1, 2026, health carriers shall provide initial 10
coverage of three monthly immunomodulatory courses of intravenous 11
immunoglobulin therapy for the treatment of pediatric autoimmune 12
neuropsychiatric disorders associated with streptococcal infections 13
and pediatric acute-onset neuropsychiatric syndrome, and subsequent 14
courses as deemed medically necessary by the treating provider, when 15
the following conditions are met: 16
(a) Clinically appropriate trials, which may be done 17
concurrently, of two or more less intensive treatments were:18
(i) Not effective; 19
(ii) Not tolerated; or 20
H-0883.2
HOUSE BILL 1741
State of Washington 69th Legislature 2025 Regular Session
By Representatives Thai, Leavitt, Paul, Simmons, Couture, Parshley,
Fey, Duerr, Nance, and Davis
Read first time 01/30/25. Referred to Committee on Health Care &
Wellness.
p. 1 HB 1741
(iii) Did not result in sustained improvement in symptoms, as 1
measured by a lack of clinically meaningful improvement on a 2
validated instrument directed at the patient's primary symptom 3
complex; and 4
(b) A pediatric subspecialist is consulted and the pediatric 5
subspecialist and the patient's primary care provider recommend the 6
treatment. For an adolescent or adult patient, the consultation may 7
be with an adult subspecialist. The subspecialist consultation may be 8
a teleconsultation. 9
(2) The health carrier may require that the patient be clinically 10
reevaluated at three-month intervals. 11
--- END ---
p. 2 HB 1741